Hoth Therapeutics Collaborates with Washington University on NIH Grant Application Advancing Alzheimer's Program Using NK-1 Receptor Antagonist HT-ALZ

Rhea-AI Summary

Hoth Therapeutics (NASDAQ: HOTH) has partnered with Washington University School of Medicine in St. Louis on an NIH grant application to advance Alzheimer's disease research using HT-ALZ, an FDA-approved NK-1 receptor antagonist.

The research, led by Dr. Carla M. Yuede, aims to understand the mechanisms behind HT-ALZ's cognitive benefits. Preclinical studies have shown promising results:

• Significant improvement in cognitive functions
• Reduced anxiety-like behaviors
• Decreased astrocyte-driven neuroinflammation in APP/PS1 mouse models
• 15% reduction in brain interstitial fluid Aβ40 levels within 20 hours of acute treatment

The company has provided GMP-quality HT-ALZ to support the studies. If funded, the grant will investigate NK-1 receptor antagonism's cellular specificity and its potential for treating neuroinflammatory conditions.

Positive

• FDA-approved NK-1 receptor antagonist shows promising preclinical results
• 15% reduction in brain interstitial fluid Aβ40 levels in acute treatment
• Significant cognitive improvement and reduced neuroinflammation in mouse models
• Potential NIH grant funding could accelerate research and development

Negative

• Still in early preclinical stage, far from market approval
• NIH grant funding not yet secured
• Efficacy in human patients remains unproven

News Market Reaction – HOTH

+0.38%

1 alert

+0.38% News Effect

On the day this news was published, HOTH gained 0.38%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

NEW YORK, April 2, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused clinical-stage biopharmaceutical company, today announced its collaboration with Washington University School of Medicine in St. Louis to advance Alzheimer's disease research through a novel therapeutic strategy. The partnership centers on a recently submitted NIH grant proposal focused on studying HT-ALZ—an FDA-approved NK-1 receptor antagonist—for its potential to reduce neuroinflammation and improve cognitive function in Alzheimer's disease (AD).

The research collaboration is led by Dr. Carla M. Yuede, Professor in the Departments of Psychiatry, Neurology, and Neuroscience, and Director of the Animal Behavior Core at Washington University. The proposal, titled "Cell Type Specificity of Neurokinin-1 Receptor Antagonists on Cognitive Improvement," aims to understand the precise neurological mechanisms and cellular targets responsible for the beneficial cognitive effects observed with HT-ALZ.

In preclinical studies conducted at Washington University, chronic oral administration of HT-ALZ significantly improved cognitive functions, reduced anxiety-like behaviors, and decreased astrocyte-driven neuroinflammation in the APP/PS1 mouse model of Alzheimer's. Acute treatment also reduced brain interstitial fluid Aβ40 levels by approximately 15% within 20 hours.

Robb Knie, Chief Executive Officer of Hoth Therapeutics, commented, "We are proud to support Dr. Yuede and her team at Washington University. This grant application represents a significant milestone in our commitment to understanding NK-1 receptor biology and its role in neurological diseases, specifically Alzheimer's. We believe that HT-ALZ, with its established safety profile, holds tremendous promise as a therapeutic intervention."

The company has supplied GMP-quality HT-ALZ to Washington University to support these studies, ensuring adherence to the highest standards of preclinical research. If funded, the grant will further elucidate the cellular specificity of NK-1 receptor antagonism and its broader implications for treating neuroinflammatory conditions.

About Hoth Therapeutics, Inc.

Hoth Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative, impactful, and ground-breaking treatments with a goal to improve patient quality of life. We are a catalyst in early-stage pharmaceutical research and development, elevating drugs from the bench to pre-clinical and clinical testing. Utilizing a patient-centric approach, we collaborate and partner with a team of scientists, clinicians, and key opinion leaders to seek out and investigate therapeutics that hold immense potential to create breakthroughs and diversify treatment options. To learn more, please visit https://ir.hoththerapeutics.com/ .

Forward-Looking Statement

This press release includes forward-looking statements based upon Hoth's current expectations, which may constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995 and other federal securities laws, and are subject to substantial risks, uncertainties, and assumptions. These statements concern Hoth's business strategies; the timing of regulatory submissions; the ability to obtain and maintain regulatory approval of existing product candidates and any other product candidates we may develop, and the labeling under any approval we may obtain; the timing and costs of clinical trials, and the timing and costs of other expenses; market acceptance of our products; the ultimate impact of the current coronavirus pandemic, or any other health epidemic, on our business, our clinical trials, our research programs, healthcare systems, or the global economy as a whole; our intellectual property; our reliance on third-party organizations; our competitive position; our industry environment; our anticipated financial and operating results, including anticipated sources of revenues; our assumptions regarding the size of the available market, benefits of our products, product pricing, and timing of product launches; management's expectation with respect to future acquisitions; statements regarding our goals, intentions, plans, and expectations, including the introduction of new products and markets; and our cash needs and financing plans. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. You should not place reliance on these forward-looking statements, which include words such as "could," "believe," "anticipate," "intend," "estimate," "expect," "may," "continue," "predict," "potential," "project" or similar terms, variations of such terms, or the negative of those terms. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee such outcomes. Hoth may not realize its expectations, and its beliefs may not prove correct. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, market conditions and the factors described in the section titled "Risk Factors" in Hoth's most recent Annual Report on Form 10-K and Hoth's other filings made with the U. S. Securities and Exchange Commission. All such statements speak only as of the date made. Consequently, forward-looking statements should be regarded solely as Hoth's current plans, estimates, and beliefs. Investors should not place undue reliance on forward-looking statements. Hoth cannot guarantee future results, events, levels of activity, performance, or achievements. Hoth does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events, or circumstances or to reflect the occurrences of unanticipated events, except as may be required by applicable law.

Investor Contact:
LR Advisors LLC 
Email: investorrelations@hoththerapeutics.com
www.hoththerapeutics.com
Phone: (678) 570-6791

View original content to download multimedia:https://www.prnewswire.com/news-releases/hoth-therapeutics-collaborates-with-washington-university-on-nih-grant-application-advancing-alzheimers-program-using-nk-1-receptor-antagonist-ht-alz-302417942.html

SOURCE Hoth Therapeutics, Inc.

FAQ

What are the key findings from HT-ALZ preclinical trials for Alzheimer's treatment?

Preclinical studies showed improved cognitive functions, reduced anxiety behaviors, decreased neuroinflammation, and a 15% reduction in brain interstitial fluid Aβ40 levels within 20 hours.

How does Hoth Therapeutics' HT-ALZ work in treating Alzheimer's disease?

HT-ALZ is an FDA-approved NK-1 receptor antagonist that targets neuroinflammation and aims to improve cognitive function in Alzheimer's disease patients.

What is the focus of HOTH's collaboration with Washington University?

The collaboration focuses on studying HT-ALZ's neurological mechanisms and cellular targets through an NIH grant proposal titled 'Cell Type Specificity of Neurokinin-1 Receptor Antagonists on Cognitive Improvement.'

What stage of development is HOTH's Alzheimer's treatment HT-ALZ in?

HT-ALZ is in preclinical development, with studies conducted at Washington University showing promising results in mouse models of Alzheimer's disease.